Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Slightly Bullish +15

Moderna (MRNA) Stock Price, Quote, Charts & News - Invezz

🧬 Moderna utilizes mRNA technology to develop medicines for infectious diseases, oncology, and rare genetic disorders.

📉 Analyst sentiment is mixed with 64% of analysts currently rating the stock as a Hold.

💸 Insiders were net sellers of approximately $6.2M in Moderna stock over the last 90 days.

📈 Technical signals are strongly bullish with the price trading above key moving averages.

🚀 MACD momentum and RSI indicators currently support a positive long-term trend for the stock.

Bullish Signals
  • Technical indicators show strong bullish momentum, with the stock price trading above both the 50-day and 200-day moving averages.
  • MACD momentum is supportive, indicating continued upward pressure on the share price.
  • The Relative Strength Index (RSI) is currently in a bullish configuration, suggesting positive market sentiment.
Risk Factors
  • Analyst sentiment is mixed, with a majority of analysts (64%) rating the stock as a Hold rather than Buy.
  • Insider selling has been the main negative factor, with net sales of approximately $6.2M recorded over the last 90 days.
  • No meaningful insider purchases were recorded recently, which may signal a lack of confidence from company insiders.
Full Analysis
Moderna, Inc. (MRNA) is a biotechnology company that transitioned from a platform-stage entity to a commercial vaccine producer following the global success of its COVID-19 vaccine. The company leverages messenger RNA technology to direct cells in producing proteins for immune responses or addressing disease biology across infectious diseases, oncology, and rare genetic conditions. The article provides a technical and fundamental snapshot of MRNA as of June 19, 2026. Analyst sentiment is currently mixed with 64% of analysts rating the stock as a Hold, while insider selling has been the primary negative factor over the last 90 days, with net sales of approximately $6.2M. Despite the insider selling, technical indicators present a strongly bullish outlook. The stock price trades above both the 50-day and 200-day moving averages, supported by positive MACD momentum and a bullish Relative Strength Index (RSI). No meaningful insider purchases were recorded during the recent period.